Filing Flows › Iovance Biotherapeutics (IOVA) › Guidance & outlook
Iovance Biotherapeutics (IOVA) guidance and outlook
Iovance Biotherapeutics (IOVA) reaffirmed its guidance on Nov 5, 2026: Revenue $410M–$420M for FY2026. Iovance Biotherapeutics' 10-Q filed Nov 5, 2026 makes 21 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $410M–$420M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We plan to launch into additional markets with a high prevalence of advanced melanoma.
- We have commenced a registrational trial in previously treated advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, and plan to engage with the FDA for an expedited path to accelerated approval.
- We plan to initiate OPTILISM, an innovative frontline trial in biomarker-enriched non-squamous mNSCLC, in 2027.
- Educating, training, and collaborating with healthcare professionals, or HCPs, who will be administering our product at academic and community authorized treatment centers, or ATCs, as well as community oncologists and advocacy groups who will refer patients to our ATCs;
- Certain clinical trials for our next-generation investigational TIL cell therapies will continue to be supported by contract manufacturing organizations, or CMOs.
- More than 50 of these patents are related to our Gen 2 TIL manufacturing processes and have terms that we anticipate will extend to October 2037 or January 2038, not including any patent term extensions or adjustments that may be available.
- We expect to continue to incur research and development expenses for the foreseeable future as we continue to conduct our clinical trials for our various product candidates.
- We anticipate selling, general, and administrative expenses will increase as we expand the use of Amtagvi ® and market Proleukin ® , as well as expected growth in the internal general and administrative team to align with the overall growth in the business as we execute an expected expansion in both the U.S. market and outside of the U.S.
- As it relates to revenue timing for our products, Amtagvi ® infusions are expected to lag behind Amtagvi ® related Proleukin ® sales by 2-3 months, and we expect ATCs to utilize approximately 15 Proleukin ® vials per Amtagvi ® infusion.
- For direct research and development expenses, we track specific project research and development expenses that are directly attributable to our preclinical and clinical development candidates that have been selected for further development.
- As such, we do not maintain information regarding those costs incurred on a project specific basis.
- Expense in 2025 was primarily related to severance payments, costs for outplacement services, and post-employment benefits associated with our August 2025 strategic restructuring plan, resulting from a review of current strategic priorities, the strategic restructuring plan included an associated reduction in workforce, resource allocations, and costs, intended to reduce operating costs, streamline operations and…
Iovance Biotherapeutics' latest quarter
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Iovance Biotherapeutics raise or lower its guidance?
Iovance Biotherapeutics (IOVA) reaffirmed its guidance on Nov 5, 2026: Revenue $410M–$420M for FY2026.
What does Iovance Biotherapeutics expect?
We plan to launch into additional markets with a high prevalence of advanced melanoma. We have commenced a registrational trial in previously treated advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, and plan to engage with the FDA for an expedited path to accelerated approval. We plan to initiate OPTILISM, an innovative frontline trial in biomarker-enriched non-squamous mNSCLC, in 2027.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.